Gastrointestinal Disorders (Jan 2023)

The Frequency and Characteristics of Severe Liver-Related Adverse Events in Patients with Chronic Liver Diseases after Vaccination against Severe Acute Respiratory Syndrome Coronavirus 2: A Retrospective Study

  • Oyunjargal Bat-Erdene,
  • Kouichi Miura,
  • Hiroshi Maeda,
  • Shunji Watanabe,
  • Mamiko Tsukui,
  • Yoshinari Takaoka,
  • Hiroaki Nomoto,
  • Rie Goka,
  • Naoki Morimoto,
  • Hironori Yamamoto

DOI
https://doi.org/10.3390/gidisord5010002
Journal volume & issue
Vol. 5, no. 1
pp. 15 – 27

Abstract

Read online

Background: Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is recommended for patients with chronic liver diseases as the vaccine can prevent and/or reduce the severity of SARS-CoV-2 infection. However, we have little information on the often-reported liver-related adverse events (LrAEs) caused by the mRNA vaccine. Methods: We retrospectively investigated the frequency and details of severe LrAEs and changes in liver function tests in patients with chronic liver diseases. Results: Among 431 patients with chronic liver diseases, 416 (96.5%) had received the SARS-CoV-2 vaccine ≥ 2 times. Among the 345 patients included in the analysis, 6 (1.7%) had severe LrAEs; 3 ascites, 2 increases in transaminases, and 1 an increase in total bilirubin. Multivariate analysis demonstrated that cirrhosis and autoimmune disease were risk factors for severe LrAEs. In contrast, the liver function reserve assessed by the Child–Pugh and ALBI scores did not markedly change after vaccination in patients with cirrhosis and/or autoimmune diseases despite a small increase in transaminase levels. Conclusion: SARS-CoV-2 mRNA vaccines, which were used in most of our patients, are safe in patients with chronic liver diseases, but the frequency of severe LrAEs is slightly increased in patients with cirrhosis and/or autoimmune diseases.

Keywords